Researchers Engineered New Marker Virus for PRRSV Control
A modified PRRSV-2 virus enables serological differentiation between vaccinated and infected swine.
Updated on Sept. 24, 2026 in Life Sciences
Live Poll
Should the agricultural industry prioritize development of new DIVA-capable vaccines for livestock disease management?
Researchers have engineered a PRRSV-2 marker virus, rGSWW15/N∆93, that allows for the distinction between vaccinated animals and those exposed to the wild-type virus. This development addresses a long-standing limitation in porcine reproductive and respiratory syndrome control efforts.
Why it matters
Current PRRSV vaccines make it impossible to differentiate between immunized animals and those naturally infected, complicating disease eradication. This new tool enables accurate serological surveillance required to manage the virus in swine populations.
The mutant virus was created by deleting the LSDSGRISYTVE epitope at the C terminus of the nucleocapsid protein. This specific deletion prevents detection by a newly developed competitive ELISA, while still eliciting detectable responses via commercial ELISA.
The players
Journal of Virology
A peer-reviewed scientific journal focused on the study of virus biology and host-pathogen interactions.
The details
Researchers produced the C8 monoclonal antibody—a lab-grown antibody that binds to a specific target—using fluorescence-based single-B-cell antibody technology to map the PRRSV nucleocapsid protein. By identifying the LSDSGRISYTVE sequence, the team created the rGSWW15/N∆93 mutant. This marker virus functions by removing the target site for the C8 antibody, allowing diagnostic tools to distinguish between the immune response triggered by the vaccine and the response from a wild-type infection.
Timeline
September 24, 2026: Study published in the Journal of Virology.
The Tech Race
This development follows a pattern set by the ongoing global research program for PRRSV vaccine development to improve diagnostic capabilities in animal health. It represents a shift from conventional whole-virus vaccines toward marker-based strategies that enable DIVA—differentiation of infected from vaccinated animals.
The tool enables veterinarians and producers to distinguish vaccinated pigs from infected herds, supporting more effective disease management. Wide adoption depends on the development of full-scale vaccines utilizing this marker and their subsequent regulatory approval.
The takeaway
This marker virus provides a necessary technical foundation for DIVA strategies in the swine industry. Watch for clinical trial announcements or further validation studies that assess the virus's performance in field-level vaccination campaigns.
Further reading
For more on emerging diagnostic methodologies, visit Life Sciences.
More information
Read the Full scientific study text to review the methodology and results.
Source note: This article includes information reported by Journal of Virology.
Live Poll
Should the agricultural industry prioritize development of new DIVA-capable vaccines for livestock disease management?
